Stryker Co. (NYSE:SYK) Shares Sold by Segall Bryant & Hamill LLC

Segall Bryant & Hamill LLC lowered its holdings in shares of Stryker Co. (NYSE:SYK - Free Report) by 2.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 59,822 shares of the medical technology company's stock after selling 1,498 shares during the quarter. Segall Bryant & Hamill LLC's holdings in Stryker were worth $21,539,000 at the end of the most recent reporting period.

Other large investors also recently added to or reduced their stakes in the company. Meridian Wealth Management LLC purchased a new position in shares of Stryker during the 3rd quarter worth $665,000. Swedbank AB boosted its position in shares of Stryker by 10.9% during the third quarter. Swedbank AB now owns 51,070 shares of the medical technology company's stock worth $18,450,000 after buying an additional 5,032 shares during the period. Summit Trail Advisors LLC grew its stake in shares of Stryker by 8.7% in the third quarter. Summit Trail Advisors LLC now owns 5,494 shares of the medical technology company's stock valued at $1,989,000 after buying an additional 441 shares in the last quarter. Daiwa Securities Group Inc. lifted its stake in Stryker by 12.3% during the 3rd quarter. Daiwa Securities Group Inc. now owns 49,003 shares of the medical technology company's stock worth $17,703,000 after acquiring an additional 5,368 shares in the last quarter. Finally, Davis R M Inc. boosted its holdings in Stryker by 2.7% during the 3rd quarter. Davis R M Inc. now owns 123,960 shares of the medical technology company's stock valued at $44,782,000 after acquiring an additional 3,279 shares during the period. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Insider Buying and Selling

In other Stryker news, Director Ronda E. Stryker sold 201,392 shares of the business's stock in a transaction on Friday, January 31st. The shares were sold at an average price of $392.24, for a total value of $78,993,998.08. Following the transaction, the director now directly owns 3,642,075 shares of the company's stock, valued at approximately $1,428,567,498. The trade was a 5.24 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Allan C. Golston sold 2,458 shares of the company's stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total transaction of $941,586.06. Following the transaction, the director now owns 14,895 shares of the company's stock, valued at approximately $5,705,827.65. The trade was a 14.16 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 5.90% of the company's stock.

Wall Street Analysts Forecast Growth

SYK has been the topic of several research reports. JMP Securities reissued a "market perform" rating on shares of Stryker in a research report on Tuesday, February 18th. JPMorgan Chase & Co. raised their price target on shares of Stryker from $420.00 to $445.00 and gave the company an "overweight" rating in a research report on Wednesday, January 29th. Canaccord Genuity Group upped their price objective on Stryker from $420.00 to $435.00 and gave the stock a "buy" rating in a research report on Wednesday, January 29th. Barclays lifted their target price on Stryker from $418.00 to $443.00 and gave the company an "overweight" rating in a report on Monday, February 10th. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $442.00 price target on shares of Stryker in a research report on Friday, March 21st. Five analysts have rated the stock with a hold rating and sixteen have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $421.90.

Stryker Stock Performance

NYSE SYK traded down $3.16 during trading hours on Friday, hitting $364.38. The company had a trading volume of 1,274,307 shares, compared to its average volume of 1,289,456. The business has a 50 day moving average of $384.08 and a 200-day moving average of $374.32. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.32 and a current ratio of 1.95. Stryker Co. has a 1-year low of $314.93 and a 1-year high of $406.19. The company has a market cap of $139.08 billion, a PE ratio of 46.96, a price-to-earnings-growth ratio of 2.93 and a beta of 0.95.

Stryker (NYSE:SYK - Get Free Report) last released its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same quarter in the prior year, the firm posted $3.46 EPS. As a group, equities research analysts expect that Stryker Co. will post 13.47 EPS for the current year.

Stryker Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be paid a dividend of $0.84 per share. The ex-dividend date of this dividend is Monday, March 31st. This represents a $3.36 annualized dividend and a dividend yield of 0.92%. Stryker's dividend payout ratio (DPR) is 43.30%.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.